Literature DB >> 305893

Partial purification and characterization of the human lymphocyte colony enhancing factor (LCEF).

A Zeevi, I Goldman, L A Rozenszajn.   

Abstract

The cloning potential of PHA-treated T cells is significantly enhanced when lymphocyte culture fluid (LCF) from mitogen-treated lymphocytes is added to the soft agar culture system. The mitogens seem to stimulate the release of a lymphocyte colony enhancing factor (LCEF) into the culture medium. A study of the physico-chemical properties of the LCEF revealed that it is a nondialyzable, heat-labile molecule which migrates in the haptoglobin (2--2) post-transferrin region in acrylamide electrophoresis. It is stable to RNase and DNase but labile to papain and trypsin. The LCEF was partially purified from the crude LCF using a sequence of techniques--ammonium sulphate precipitation, DEAE-cellulose and Bio-Gel P-150 chromatography and disc electrophoresis. The mol. wt of the purified LCEF, determined from gel filtration chromatography, was 90,000--110,000.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 305893      PMCID: PMC1457598     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  SEPARATION OF LYMPHOCYTES, POLYMORPHONUCLEAR LEUKOCYTES AND MONOCYTES ON GLASS COLUMNS, INCLUDING TISSUE CULTURE OBSERVATIONS.

Authors:  Y RABINOWITZ
Journal:  Blood       Date:  1964-06       Impact factor: 22.113

2.  DISC ELECTROPHORESIS. I. BACKGROUND AND THEORY.

Authors:  L ORNSTEIN
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

3.  Influence of ether, in vitro, on pathogenic properties of mouse leukemia extracts.

Authors:  L GROSS
Journal:  Acta Haematol       Date:  1956-05       Impact factor: 2.195

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Stimulation and inhibition of human T-lymphocyte colony cell proliferation by hemopoietic cell factors.

Authors:  A Zeevi; I Goldman; L A Rozenszajn
Journal:  Cell Immunol       Date:  1977-02       Impact factor: 4.868

6.  A procedure for rapid and sensitive staining of protein fractionated by polyacrylamide gel electrophoresis.

Authors:  A Chrambach; R A Reisfeld; M Wyckoff; J Zaccari
Journal:  Anal Biochem       Date:  1967-07       Impact factor: 3.365

Review 7.  The regulatory influence of activated T cells on B cell responses to antigen.

Authors:  D H Katz; B Benacerraf
Journal:  Adv Immunol       Date:  1972       Impact factor: 3.543

8.  Direct observations on the effect of "proliferation inhibitory factor" on the clonal growth of target cells.

Authors:  A M Badger; S R Cooperband; J A Green
Journal:  J Immunol       Date:  1971-11       Impact factor: 5.422

9.  Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction.

Authors:  G A Granger; W P Kolb
Journal:  J Immunol       Date:  1968-07       Impact factor: 5.422

10.  Colony growth in vitro of mitogen-stimulated mouse B lymphocytes.

Authors:  L A Rozenszajn; H Michlin; Y Kalechman; B Sredni
Journal:  Immunology       Date:  1977-03       Impact factor: 7.397

View more
  3 in total

1.  Activation of human lymphocytes by supernatants from human thymic epithelium.

Authors:  J M Goust; D H Vesole; H H Fudenberg
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

2.  Identification and partial purification of human T lymphocyte colony-enhancing factor (LCEF), distinct from T cell-growth factor.

Authors:  M M Werber; D Daphna; J Goldman; D Joseph; J Radnay; L A Rozenszajn
Journal:  Immunology       Date:  1983-10       Impact factor: 7.397

3.  Identification and purification of human T-lymphocyte colony-enhancing factor, TLCEF: increased production by phorbol myristate acetate.

Authors:  M M Werber; J Goldman; J Radnay; S Klein; L A Rozenszajn
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.